What are the Therapeutic Implications of Targeting the UPS in Cancer?
Targeting the UPS has emerged as a promising therapeutic strategy in cancer treatment. The proteasome inhibitor bortezomib is one of the first drugs to exploit this pathway and is used in treating multiple myeloma and certain lymphomas. By inhibiting the proteasome, bortezomib induces apoptosis in cancer cells by stabilizing pro-apoptotic factors and inhibiting NF-kB signaling. Research is ongoing to develop more selective inhibitors that target specific components of the UPS, such as E3 ligases, to minimize side effects and improve efficacy.
